

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number  
WO 03/077830 A2

(51) International Patent Classification<sup>2</sup>: A61K CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/IB03/00987

(22) International Filing Date: 18 March 2003 (18.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

P20020231A	18 March 2002 (18.03.2002)	HR
60/393,612	3 July 2002 (03.07.2002)	US
60/394,705	8 July 2002 (08.07.2002)	US

(71) Applicant: PLIVA D.D. [HR/HR]; Ulica grada Vukovara 49, 10000 Zagreb (HR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A



[H<sub>2</sub>O]<sub>x</sub> [S]<sub>y</sub> (I)

(57) Abstract: Substantially pure isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A having the Formula I: wherein S is an organic solvent which is at least partially miscible with water, x is 1, 1.25, 1.5 or 2, y is 0, 0.5, or 1, the pseudopolymorph being characterized by the monoclinic space group *P*2<sub>1</sub> and average unit cell parameters comprising: crystal axis lengths of a = 15.5 - 17.0 Å, b = 15.5 - 17.0 Å, and c = 17.5 - 19.5 Å, and angles between the crystal axes of  $\alpha$  =  $\gamma$  = 90° and  $\beta$  = 106° - 112°. In addition, this disclosure is directed to processes for the preparation of the substantially pure isostructural pseudopolymorphs of Formula I; to pharmaceutical compositions containing

WO 03/077830 A2

substantially pure isostructural pseudopolymorphs of Formula I; and to a method for the treatment of bacterial and protozoan infections, and inflammation-related diseases by administration of a pharmaceutical composition containing the substantially pure isostructural pseudopolymorphs of Formula I.

5

**ISOSTRUCTURAL PSEUDOPOLYMORPHS OF  
9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A**

Under 35 U.S.C. § 119(e), this application claims the benefit of prior U.S. Provisional Application No. 60/394,705, filed July 8, 2002, and prior U.S. Provisional Application No. 60/393,612, filed July 3, 2002, the entire contents of which are incorporated herein 10 by reference.


Under 35 U.S.C. § 119, this application claims priority from Croatian Patent Application No. P20020231A, filed March 18, 2002.

**FIELD OF THE INVENTION**

This invention relates to new isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-15 methyl-9a-homoerythromycin A, to a process for the preparation of such pseudopolymorphs, to pharmaceutical formulations incorporating the same and to methods of use of such formulations in the treatment of bacterial and protozoan infections, and inflammation-related diseases.

**BACKGROUND OF THE INVENTION**

20 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A is the first and still the only marketed 15-membered semi-synthetic macrolide antibiotic from the group of azalides [The Merck Index, 12<sup>th</sup> Ed. (1996), p. 157 (946)]. It has the formula



The synthesis of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A is described in U.S. Patent No. 4,517,359. Its antibacterial spectrum (J. Antimicrob. Chemother., 1987, 19, 275), mode of action (Antimicrob. Ag. Chemother., 1987, 31, 1939) and pharmacology (J. 5 Antimicrob. Chemother. 1993, 31, Suppl. E, 1-198) are well known.

9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A occurs in amorphous form, and in several different crystal forms characterized by different arrangements of the atoms in the crystal network. Most of the forms are crystalline, their crystal unit cells containing, in addition to 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, different numbers of water 10 molecules and/or solvent molecules (pseudopolymorphs).

Anhydrous amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, having a melting point of 113-115°C, is described in U.S. Patent No. 4,517,359. It may be obtained by evaporation of the solvent from a chloroform solution of crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. It is not crystalline but rather an amorphous product, resembling a 15 solid foaming mass. A pure laboratory scale product may be obtained, either by chromatography of the crude final product or by dissolution of pure crystalline 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A monohydrate or dihydrate in an organic solvent, followed by evaporation of the solvent. Pure amorphous anhydrous 9-deoxo-9a-aza-9a-

methyl-9a-homoerythromycin A may be thus obtained. This procedure is not suitable for large-scale manufacture.

The preparation of various amorphous, crystalline solvated and hydrated forms of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A has been described in the patent literature. See, for example, U.S. 4,474,768; U.S. 6,245,903; EP 1 103 558; CN 1 093370; CN 1 161971; WO 99/58541; WO 00/32203; WO 01/00640; WO 02/09640; WO 02/10144; WO 02/15842 ; WO 02/10181 and WO 02/42315. Materials so produced have been subject to various disadvantages including lack of purity, instability, hygroscopicity, and the like.

Non-hygroscopic 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate was prepared as early as the mid-1980's by neutralization of an acidic solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A in an acetone-water mixture. Its crystal structure (single crystal) was evaluated upon recrystallization from ether, and was characterized by the orthorhombic space group  $P\ 2_12_12_1$ . The unit cell parameters, namely crystal axes  $a = 17.860\ \text{\AA}$ ,  $b = 16.889\ \text{\AA}$  and  $c = 14.752\ \text{\AA}$ , and the angles between the crystal axes,  $\alpha = \beta = \gamma = 90^\circ$ , were published in 1987 at the Meeting of Chemists of Croatia (Book of Abstracts, Meeting of Chemists of Croatia, Feb. 19-20, 1987, p. 29). Thereafter, its crystal structure and preparation were described in detail (J. Chem. Res. (S), 1988, 152, Ibid., miniprint 1988, 1239; received June 4, 1987; Cambridge Crystallographic Data Base: GEGJAD).

Subsequently, in U.S. Patent No. 6,268,489 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate was described. That patent disclosed the preparation of the dihydrate by crystallization from tetrahydrofuran and hexane with the addition of water. The product thus formed is crystalline and can be obtained on a commercial scale in pure form.

Its preparation is however subject to several disadvantages associated with the use of water-immiscible, toxic organic solvents and the necessity to carefully control the drying thereof.



Other techniques for preparing the dihydrate have been disclosed in the patent literature, e.g., in U.S. 5,869,629; EP 0 941 999; EP 1 103 558; HR P 921491; WO 01/49697; 5 and WO 01/87912. Various of the procedures described involve the precipitation of the dihydrate by recrystallization from water-miscible solvents by the addition of water. The products formed by these and other processes described in the literature are however subject to a number of distinct disadvantages, ranging from the necessity to treat pharmaceutically pure 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A materials to the yield, purity and 10 homogeneity of the products themselves. Indeed, products formed by various of the prior art techniques incorporate differing amounts of combined and adsorbed solvents and water, thus imparting inconsistent stability, purity, release and potency characteristics when incorporated in pharmaceutical formulations.

It is among the objects of the present invention to provide a number of new, 15 isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of predetermined crystalline structures and which, by virtue of such structures, provide more consistent, predictable properties in pharmaceutical formulations.

**SUMMARY OF THE INVENTION**

This invention relates to new isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, having the formula I

5



10 wherein

S is an organic solvent which is at least partially miscible with water,

x is 1, 1.25, 1.5 or 2,

y is 0, 0.5, or 1,

the pseudopolymorphs being characterized by the monoclinic space group  $P\ 2_1$  and a range of

15 unit cell parameters of

crystal axis lengths from  $a = 15.5 - 17.0 \text{ \AA}$ ,  $b = 15.5 - 17.0 \text{ \AA}$  and  $c = 17.5 - 19.5 \text{ \AA}$ ,

and

angles between the crystal axes of  $\alpha = \gamma = 90^\circ$  and  $\beta = 106 - 112^\circ$

The isostructural pseudopolymorphs hereof comprise the individual crystal entities 20 identified as compounds Ia-Im in Table 1 below, whose crystal packing is illustrated in Figures 2-14 of the annexed drawings. As illustrated, they are compounds having unique crystal packing with discrete channel formation within their unit cells (see Figure 15). As a consequence of the channel formation water and/or solvent molecules can be fitted into their cavities and removed upon drying to provide isostructural solid state forms, i.e., the

pseudopolymorphs of the invention, which have unique crystalline structures as characterized by their monoclinic space group  $P2_1$  and the lengths of their crystal axes and intermediate angles of their unit cells.

It is textbook knowledge that hydrates and/or solvates in general, of any compound

5 should be defined as solid state forms that must have crystal water and/or solvent molecules in the asymmetric unit of the crystal unit cell besides the core compound moiety. Moreover, these hydrated and/or solvated molecules must be found in stoichiometric ratio to the core compound moiety, and are therefore clearly distinguishable from adsorbed water and/or solvent molecules.

10 X-ray crystallography is the only method that should be used as an analytically unambiguous and valid characterization of such hydrates and/or solvates. Various thermal methods (e.g. TGA or DSC) together with water and/or solvent content determinations (e.g., Karl Fischer water content determinations or GC) can only be used as a supplement to x-ray crystallographic data, and can give false and speculative results. Additionally, various

15 literature data demonstrate that even a specific hydrate and/or solvate form can crystallize in different and distinct crystal entities, i.e., in distinct pseudopolymorphs. As an illustration a known antibiotic, nitrofurantoin, crystallizes in two distinct monohydrate solid state forms with exactly the same water content ( $C_8H_6N_4O_5 \cdot H_2O$ ) but with clearly distinct crystallographic data, namely monohydrate I crystallizes in the monoclinic space group

20  $P\ 2_1/n$  while monohydrate II crystallizes in the orthorhombic space group  $P\ bca$  (E. W. Pienaar, M. Caira, A. P. Lotter, J. Crystallogr. Spectrosc. Res 23 (1993) 739-744; CSDB codes HAXBUD and HAXBUD01).

Isostructural solid state forms, e.g., pseudopolymorphs, can have very similar or even identical powder diffraction patterns. Therefore, definite and unambiguous identification of

any isostructural solid state forms, e.g. pseudopolymorphs, can and should be done by single crystal x-ray diffraction.

In accordance with the present invention, the specific crystalline structures of a group of stable isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A have been determined, at least one of which pseudopolymorphs possesses a number of superior properties as compared with previously described forms of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. In particular, one pseudopolymorph of the present invention, the isostructural 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph of general formula I wherein  $x=1$ ,  $y=0$ , possesses a number of superior properties as compared with the current commercially available form of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, namely the dihydrate referred to hereinabove. Thus, that pseudopolymorph may, unlike the dihydrate, be reproducibly prepared under a wide range of preparative conditions. Second, it can be prepared directly from the native solution of crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, or from crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A itself, rather than from any purified 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material. Third, this new pseudopolymorph may be prepared in high purity and pharmaceutically acceptable quality.

Fourth, the new pseudopolymorph is an air-stable, free-flowing form of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (based on the granulated habit of its small crystals, see Figure 16.). Fifth, the new pseudopolymorph has significantly better dissolution rates in both acid and neutral media as compared with the dihydrate. Sixth, the intrinsic dissolution rate (IDR) of the pseudopolymorph is significantly higher than the dissolution rate of the dihydrate. Seventh, the new pseudopolymorph may be used in the preparation of a variety of pharmaceutical preparations intended for immediate, controlled or sustained release

applications. Finally, because of its superior dissolution characteristics this new pseudopolymorph, unlike the dihydrate or other previously known forms of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, can be successfully utilized in the preparation of rapidly acting oral and local, particularly topical, pharmaceutical formulations.

5 The present invention further relates to a process for the preparation of the new isostructural 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorphs of Formula I, which process comprises:

- (a) dissolving a 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material in (1) an organic solvent which is at least partially water-miscible, (2) a mixture of such organic solvents, (3) a mixture of the organic solvent and water or (4) a mixture of water and at least one mineral or organic acid;
- (b) crystallizing the isostructural pseudopolymorph from the solution;
- (c) isolating the isostructural pseudopolymorph; and
- (d) transforming the isostructural pseudopolymorph to a stable isostructural pseudopolymorph of Formula I wherein  $x=1$  and  $y=0$ .

Finally, the present invention also relates to pharmaceutical formulations comprising the new isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A in combination with one or more pharmaceutically acceptable carriers and other excipients, and to a method for the treatment of bacterial and protozoan infections, and inflammation-related diseases in humans or animals subject thereto, involving the administration of such pharmaceutical formulations to subjects in need of such treatment.

**BRIEF DESCRIPTION OF THE DRAWINGS**

FIGURE 1 is a crystal packing diagram of the current commercially-available 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate (the structure coded GEGJAD, described in the Cambridge Crystallographic database);

5 FIGURE 2 is a crystal packing diagram of an isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of Formula I (compound Ia:  $x=1$ ,  $y=0$ );

FIGURE 3 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Ib: S = methanol;  $x=1.25$ ,  $y=1$ );

10 FIGURE 4 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Ic: S = ethanol;  $x=1$ ,  $y=0.5$ );

FIGURE 5 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Id: 15 S = n-propanol;  $x=1$ ,  $y=0.5$ );

FIGURE 6 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Ie S = isopropanol;  $x=1.5$ ,  $y=0.5$ );

FIGURE 7 is a crystal packing diagram of a further isostructural pseudopolymorph of 20 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound If: S = n-butanol;  $x=1.5$ ,  $y=0.5$ );

FIGURE 8 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Ig: S = isobutanol;  $x=1.25$ ,  $y=0.5$ );

FIGURE 9 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Ih: S = 1,2-ethanediol; x=1, y=0.5);

FIGURE 10 is a crystal packing diagram of a further isostructural pseudopolymorph 5 of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound II: S = 1,3-propanediol; x=1, y=0.5);

FIGURE 11 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Ij: S = glycerol; x=1, y=0.5);

10 FIGURE 12 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Ik: S = glycerol; x=1.5, y=0.5);

FIGURE 13 is a crystal packing diagram of a further isostructural pseudopolymorph 15 of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Il: S = acetone; x=1, y=0.5);

FIGURE 14 is a crystal packing diagram of a further isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the invention (compound Im: S=dimethylsulfoxide (DMSO); x=1, y=0.5);

FIGURE 15 is an illustration of channel formation within the unit cell of the 20 isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of general formula I.

FIGURE 16 is an SEM of the surface of the isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of Formula I (compound Ia: x=1, y=0);

FIGURE 17 is a graph comparing the dissolution rates of the pseudopolymorph of the invention and the known 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate, at pH 3 and 37°C;

FIGURE 18 is a graph comparing the dissolution rates of the pseudopolymorph of the invention and the known 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate, at pH 6 and 37°C;

FIGURE 19 is a graph illustrating the solid state stability of the isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of Formula I (compound Ia: x=1, y=0) under various stress conditions (temperatures from 30°-70°C, and humidities from 5-75% RH).

FIGURE 20 is a graph illustrating the plasma profile of the pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of Formula I (compound Ia: x=1, y=0) and 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin dihydrate in rats after *per os* administration (50 mg/kg, b.w.)

FIGURE 21 is a graph illustrating the whole blood profile of the pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of Formula I (compound Ia: x=1, y=0) and 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin dihydrate in rats after *per os* administration (50 mg/kg, b.w.)

FIGURE 22 is a graph comparing the dissolution rates of the pseudopolymorph Ik of the invention and the known 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate, at pH 6 and 37°C;

**DETAILED DESCRIPTION OF THE INVENTION**

As used herein with reference to the isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the present invention, the term "substantially pure" denotes a pseudopolymorph of Formula I characterized by the monoclinic space group 5  $P\ 2_1$  and the average unit cell parameters identified above, that is at least 90% pure. To be more specific, the phrase "at least 90% pure" refers to the pseudopolymorphs of the present invention that contain no more than 10% of another compound, particularly not more than 10% of some other crystalline or amorphous form of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. Preferably, the "substantially pure" pseudopolymorph of the present 10 invention is "essentially pure," that is it contains 5% or less of any other compound or some other crystalline or amorphous form of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A.

In addition, as used herein, the term "9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material" utilized in step (a) of the process for forming the isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A hereof, refers to 15 any form of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, including crude or purified 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A or a solvate or hydrate thereof, in either crystalline or amorphous form; or the "native solution" of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A formed during the last step of its syntheses (e.g. from 9-deoxo-9a-aza-9a-homoerythromycin A ("9a-DeMet"), as one of its last intermediates).

20 As used herein, the term "crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A" is intended to include 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of any purity less than pharmaceutically acceptable purity, including 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A obtained prior to final purification thereof.

As used herein, the term "native solutions of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A" refers to solutions of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A in water or any organic solvents, or admixtures thereof, utilized in the final step of preparing 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A from its last 5 intermediates (e.g. from 9a-DeMet), prior to isolation of crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A.

9-Deoxo-9a-aza-9a-homoerythromycin A ("9a-DeMet") used as starting material in the presently claimed methods is also referred to in the art as 11-aza-10-deoxo-10-dihydroerythromycin A (10-dihydro-10-deoxo-11-azaerythromycin A) (US 4,328,334; J. 10 *Chem Res. (M)* 1988, 1239). It is known and obtainable e.g. by conventional methods (see: US 4,328,334; *J. Chem. Soc., Perkin Trans. I* 1986, 1881).

Solvents utilized in the native solutions of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A may include water, chlorinated solvents, e.g. haloalkanes having one or two carbon atoms such as chloroform or dichloromethane; esters of acetic acid with a C<sub>2</sub>-C<sub>4</sub> 15 lower alkyl group such as ethyl acetate, isopropyl acetate or n-butyl acetate; monohydric C<sub>2</sub>-C<sub>4</sub> alkanols such as isopropanol or 2-butanol; C<sub>1</sub>-C<sub>4</sub> ketones such as acetone or isobutylketone; or aromatic or substituted aromatic solvents such as toluene.

#### 1. Preparation of the Pseudopolymorphs of the Invention

20

##### Step (a) - Dissolving the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A Material

As disclosed above, the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material is dissolved in step (a) of the process for the preparation of the isostructural

pseudopolymorphs of the invention in (1) an organic solvent which is at least partially water-miscible, (2) a mixture of such organic solvents, (3) a mixture of the organic solvent and water or (4) a mixture of water and at least one mineral or organic acid. Organic solvents which are so useful include lower aliphatic straight or branched-chain alkanols such as 5 methanol, ethanol, *n*-propanol, isopropanol, *n*-butanol, *iso*-butanol, *sec*-butanol, *tert*-butanol or allyl alcohol; cycloalkanols, such as cyclopentanol or cyclohexanol; arylalkanols, such as benzyl alcohol; diols, such as 1,2-ethanediol, 1,2-propanediol, 1,3-propanediol, 1,4-butanediol or 2-butene-1,4-diol; triols, such as glycerol; ethers, such as diethyl ether, monoglyme, diglyme or 1,4-dioxane; ketones, such as acetone, 2-butanone; esters, such as 10 methyl formate, ethyl formate, methyl acetate, ethyl acetate or ethyl lactate; amines, such as N-methylmorpholine, amides, such as dimethylformamide or dimethylacetamide; lactams, such as 2-pyrrolidone, N-methylpyrrolidone; ureas, such as N,N,N',N'-tetramethylurea; nitriles, such as acetonitrile or propionitrile; sulfoxides, such as dimethyl sulfoxide; or sulphones, such as sulfolane.

15 The mineral or organic acids which may be utilized for acidification employed in step (a) of the process for forming the pseudopolymorphs hereof may comprise any common mineral or organic acid. Suitable examples include, but are not limited to, hydrochloric, sulfuric, sulfurous, phosphoric, carbonic, formic, acetic, propionic, citric, tartaric, maleic, oxalic, chloroacetic, benzoic, methanesulfonic or *p*-toluene sulfonic acid.

20 The dissolution of the 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A material in step (a) is carried out at temperatures of from about 0° to about 100°C, preferably at from about 0° to about 80°C and, most desirably, at temperatures of from about 5° to about 60°C.

Step (b) - Crystallization of the Pseudopolymorphs

The new isostructural pseudopolymorphs of the invention are crystallized from the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A solution in step (b) of the process hereof by either controlled cooling, isothermal saturation of the solution with water until slight turbidity of the solution occurs, or by neutralization of the acidic solution with a common inorganic or organic base.

Inorganic bases which may be so utilized include common inorganic bases, such as the hydroxides, oxides or carbonates of Groups I or II of The Periodic Table Of The Elements, e.g., the alkali metal or alkaline earth metal bases such as lithium, sodium, potassium, barium, magnesium or calcium hydroxide; sodium, magnesium or calcium oxide; sodium or potassium carbonate; ammonia solutions. Organic bases which are so useful include organic amines, such as trimethylamine, triethylamine, piperidine, 3-methylpyridine, piperazine, triethanolamine or ethylene diamine; or quaternary organic hydroxides, such as tetramethyl-, tetraethyl- or tetrabutyl-ammonium hydroxide.

The crystallization may be carried out with or without crystal seeding i.e., by the addition of small amounts of one of the pseudopolymorphs of the present invention, in amounts of from about 0.1 to about 5.0% based on the amount of the initial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material treated.

The crystallization, whether performed by controlled cooling, isothermal saturation or neutralization of the acidic solution with base, is carried out at temperatures of from about -10°C to about 80°C, preferably from about 0°C to about 40°C, and most desirably at temperatures of from about 5°C to about 25°C. The crystallization is completed in a period of from about 30 minutes to about 7 days.

Step (c) Isolating the Isostructural Pseudopolymorphs

The crystalline isostructural pseudopolymorphs hereof are isolated in step (c) in

5 conventional manner, e.g., by centrifugation, filtration or the like, operating under reduced, atmospheric or elevated pressures. The isolated pseudopolymorph is then washed in a water-miscible organic solvent (such as those described hereinabove) or in such a solvent admixed with water. The resulting intermediate product is then dried in conventional manner, e.g., by fluid bed drying, operating under atmospheric pressure at temperatures of from about 20° to

10 about 120°C, or under reduced pressures of from about 2 to about 80 kPa and at temperatures of from about 30°C to about 120°C.

15 Step (d) - Transforming the Isostructural Pseudopolymorph to a Stable Isostructural Pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A Formula I wherein x=1 and y=0

Finally, transformation of the crystalline dried (or wet) isostructural pseudopolymorph of Formula I formed in step (b) to the pseudopolymorph Ia (x=1, y=0) is carried out by removal of solvent and excess water by lyophilization, or by drying under reduced pressures

20 of from about 0.01 to about 80 kPa or at atmospheric pressure and temperatures of from about -100° to about 120°C.

The new isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of general formula I wherein x=1, y=0, produced by the process of this invention in at least substantial purity, possesses good flowability, porous crystal structure

25 (see Figure 16.) and excellent stability characteristics under varying humidity conditions (see Figure 19.). The improved properties of that pseudopolymorph relative to the commercially

available 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate are more fully disclosed in Examples 25-27 below.

## 2. Formulations of the Pseudopolymorphs of the Invention

5

The new isostructural 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorphs of the present invention can be utilized in the preparation of rapid, controlled and sustained release pharmaceutical formulations, suitable for oral, rectal, parenteral, transdermal, buccal, nasal, sublingual, subcutaneous or intravenous 10 administration. Such formulations may be useful for the treatment of bacterial and protozoan infections in humans and animals, as well as other conditions such as inflammatory diseases.

The formulations are preferably administered orally, in the form of rapid or controlled release tablets, microparticles, mini tablets, capsules and oral solutions or suspensions, or powders for the preparation thereof. In addition to the new isostructural 9-deoxo-9a-aza-9a- 15 methyl-9a-homoerythromycin A pseudopolymorphs of the present invention as the active substance, oral preparations may optionally include various standard pharmaceutical carriers and excipients, such as binders, fillers, buffers, lubricants, glidants, disintegrants, odorants, sweeteners, surfactants and coatings. Some excipients may have multiple roles in the formulations, e. g., act as both binders and disintegrants.

20

Examples of pharmaceutically acceptable disintegrants for oral formulations useful in the present invention include, but are not limited to, starch, pre-gelatinized starch, sodium starch glycolate, sodium carboxymethylcellulose, croscarmellose sodium, microcrystalline cellulose, alginates, resins, surfactants, effervescent compositions, aqueous aluminum silicates and crosslinked polyvinylpyrrolidone.

Examples of pharmaceutically acceptable binders for oral formulations useful herein include, but are not limited to, acacia; cellulose derivatives, such as methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose or hydroxyethylcellulose; gelatin, glucose, dextrose, xylitol, polymethacrylates, 5 polyvinylpyrrolidone, sorbitol, starch, pre-gelatinized starch, tragacanth, xanthane resin, alginates, magnesium-aluminum silicate, polyethylene glycol or bentonite.

Examples of pharmaceutically acceptable fillers for oral formulations include, but are not limited to, lactose, anhydrolactose, lactose monohydrate, sucrose, dextrose, mannitol, sorbitol, starch, cellulose (particularly microcrystalline cellulose), dihydro- or anhydro- 10 calcium phosphate, calcium carbonate and calcium sulfate.

Examples of pharmaceutically acceptable lubricants useful in the formulations of the invention include, but are not limited to, magnesium stearate, talc, polyethylene glycol, polymers of ethylene oxide, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, DL-leucine and colloidal silicon dioxide

15 Examples of suitable pharmaceutically acceptable odorants for the oral formulations include, but are not limited to, synthetic aromas and natural aromatic oils such as extracts of oils, flowers, fruits and combinations thereof. Preferable are vanilla and fruit aromas, including banana, apple, sour cherry, peach and similar aromas. Their use depends on many factors, the most important being the organoleptic acceptability for the population that will be 20 taking the pharmaceutical formulations.

Examples of suitable pharmaceutically acceptable dyes for the oral formulations include, but are not limited to, synthetic and natural dyes such as titanium dioxide, beta-carotene and extracts of grapefruit peel.

Examples of useful pharmaceutically acceptable coatings for the oral formulations, typically used to facilitate swallowing, modify the release properties, improve the appearance, and/or mask the taste of the formulations include, but are not limited to, hydroxypropylmethylcellulose, hydroxypropylcellulose and acrylate-methacrylate 5 copolymers.

Suitable examples of pharmaceutically acceptable sweeteners for the oral formulations include, but are not limited to, aspartame, saccharin, saccharin sodium, sodium cyclamate, xylitol, mannitol, sorbitol, lactose and sucrose.

Suitable examples of pharmaceutically acceptable buffers include, but are not limited 10 to, citric acid, sodium citrate, sodium bicarbonate, dibasic sodium phosphate, magnesium oxide, calcium carbonate and magnesium hydroxide.

Suitable examples of pharmaceutically acceptable surfactants include, but are not limited to, sodium lauryl sulfate and polysorbates.

Formulations of the isostructural 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A 15 pseudopolymorphs of the present invention can also be administered intravenously or intraperitoneally, by infusion or injection. Dispersions can also be prepared in a liquid carrier or intermediate, such as glycerin, liquid polyethylene glycols, triacetin oils, and mixtures thereof. To improve storage stability, such preparations may also contain a preservative to prevent the growth of microorganisms.

20 Pharmaceutical formulations suitable for injection or infusion may be in the form of a sterile aqueous solution, a dispersion or a sterile powder that contains the active ingredient, adjusted, if necessary, for preparation of such a sterile solution or dispersion suitable for infusion or injection. This may optionally be encapsulated into liposomes. In all cases, the final preparation must be sterile, liquid, and stable under production and storage conditions.

The liquid carrier or intermediate can be a solvent or liquid dispersive medium that contains, for example, water, ethanol, a polyol (e. g. glycerol, propylene glycol or the like), vegetable oils, non-toxic glycerine esters and suitable mixtures thereof. Suitable flowability may be maintained, by generation of liposomes, administration of a suitable particle size in 5 the case of dispersions, or by the addition of surfactants. Prevention of the action of micro-organisms can be achieved by the addition of various antibacterial and antifungal agents, e. g. paraben, chlorobutanol, or sorbic acid. In many cases isotonic substances are recommended, e. g. sugars, buffers and sodium chloride to assure osmotic pressure similar to those of body fluids, particularly blood. Prolonged absorption of such injectable mixtures can be achieved 10 by introduction of absorption-delaying agents, such as aluminium monostearate or gelatin.

Sterile injectable solutions can be prepared by mixing the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A isostructural pseudopolymorphs with an appropriate solvent and one or more of the aforementioned excipients, followed by sterile filtering. In the case of sterile powders suitable for use in the preparation of sterile injectable solutions, preferable 15 preparation methods include drying in vacuum and lyophilization, which provide powdery mixtures of the isostructural pseudopolymorphs and desired excipients for subsequent preparation of sterile solutions.

The compounds of the present invention may also be used for the preparation of locally acting, topical formulations. Such formulations may also contain other 20 pharmaceutically acceptable excipients, such as polymers, oils, liquid carriers, surfactants, buffers, preservatives, stabilizers, antioxidants, moisturizers, emollients, colorants and odorants.

Examples of pharmaceutically acceptable polymers suitable for such topical formulations include, but are not limited to, acrylic polymers; cellulose derivatives, such as

carboxymethylcellulose sodium, methylcellulose or hydroxypropylcellulose; natural polymers, such as alginates, tragacanth, pectin, xanthan and cytosan.

Examples of suitable pharmaceutically acceptable oils which are so useful include but are not limited to, mineral oils, silicone oils, fatty acids, alcohols, and glycols.

5 Examples of suitable pharmaceutically acceptable liquid carriers include, but are not limited to, water, alcohols or glycols such as ethanol, isopropanol, propylene glycol, hexylene glycol, glycerol and polyethylene glycol, or mixtures thereof in which the pseudopolymorph is dissolved or dispersed, optionally with the addition of non-toxic anionic, cationic or non-ionic surfactants, and inorganic or organic buffers.

10 Suitable examples of pharmaceutically acceptable preservatives include, but are not limited to, various antibacterial and antifungal agents such as solvents, for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts, and parabens (such as methyl paraben, ethyl paraben, propyl paraben, etc.).

15 Suitable examples of pharmaceutically acceptable stabilizers and antioxidants include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), thiourea, tocopherol and butyl hydroxyanisole.

Suitable examples of pharmaceutically acceptable moisturizers include, but are not limited to, glycerine, sorbitol, urea and polyethylene glycol.

20 Suitable examples of pharmaceutically acceptable emollients include, but are not limited to, mineral oils, isopropyl myristate, and isopropyl palmitate.

The use of dyes and odorants in topical formulations of the present invention depends on many factors of which the most important is organoleptic acceptability to the population that will be using the pharmaceutical formulations.

The therapeutically acceptable quantity of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A isostructural pseudopolymorphs of the present invention administered varies, dependent on the selected compound, the mode of administration, treatment conditions, age and status of the patient or animal species, and is subject to the final decision 5 of the physician, clinician or veterinary doctor monitoring the course of treatment.

Suitable oral and parenteral doses may vary within the range of from about 1 to about 200 mg per kg of body weight per day, preferably from about 5 to about 100 mg per kg of body weight and more preferably from about 5 to about 50 mg per kg of body weight per day. The 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorphs may be 10 formulated in a single dosage form that contains from about 1 to about 3000 mg, preferably from about 100 to about 200 mg, and more desirably from about 150 to about 600 mg of the active substance per unit dose.

#### EXAMPLES

The isostructural pseudopolymorphs of the present invention were prepared as 15 described in Examples 1-22 below, utilizing 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A in various purities and crystalline forms, including anhydrous, hydrated and solvated forms, as substrates initially used therein. The various 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A materials so utilized were commercially available or prepared in the manner disclosed in the prior art, to the extent that the conditions therein 20 could be ascertained. In the experiments reported in the examples, the contents of the respective 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A products were analyzed by HPLC, and residual solvent contents were determined by GC. Particle sizes and distributions were obtained by the Malvern Method. TGA and DSC measurements were performed on Perkin-Elmer instruments, SEM scans were performed on Jeol JFM-5800, and diffraction

experiments were performed on Bruker-Nonius FR591/KappaCCD single crystal X-ray diffractometer and Philips XPertPRO powder X-ray diffractometer equipped with Anton Paar TTK-100 humidity camera used for non-ambient data collection. The crystal structures of the several pseudopolymorphs thus produced are indicated in Table 1 below, and the 5 conditions employed in their preparation are given in Tables 2 and 3.

Formulations containing the new isostructural pseudopolymorph of general formula I wherein x=1, y=0 of Examples 11 and 14 to 21 are described in Examples 23 and 24, and comparative data indicating the potential consistent bioavailability, and superior dissolution and stability properties of the new pseudopolymorph, relative to the commercial 9-deoxo-9a-10 aza-9a-methyl-9a-homoerythromycin A dihydrate product are given in Examples 25-26.

### Preparation Of The Pseudopolymorphs

#### **Example 1**

15        **Preparation of Pseudopolymorph of Formula II (S=acetone, x=1, y=0.5)  
By Precipitation From Acetone/Water  
(Method A)**

The intermediate 9-deoxo-9a-aza-9a-homoerythromycin (9a-DeMet), obtained by 20 method A of US 4,328,334, was reacted with formic acid (1.8-2.5 mole/mole 9a-DeMet) and formalin (1-1.5 mole formaldehyde/mole 9a-DeMet) in acetone (4-8 l/kg of the 9a-DeMet material). The mixture was heated to its boiling point (about 56°C) and stirred at that temperature for 4 hours.

The reaction mixture was thereafter cooled and activated charcoal was added thereto. 25 After stirring the mixture was filtered, and the charcoal remaining on the filter was washed with acetone (0.5-2.0 l/kg of the 9a-DeMet substrate). The combined acetone solution (both

the filtrate and the wash) was then added to the water (10-20 l/kg of the 9a-DeMet). Product crystals were thus partially precipitated.

The resulting mixture was alkalized stepwise with 10% sodium hydroxide to a pH of 9.8, and then stirred at room temperature for 2 hours. The precipitate was a crystalline, 5 isostructural pseudopolymorph of Formula I (II: S = acetone, x=1 and y=0.5). The precipitate was filtered, washed with an aqueous acetone solution (10% V/V) and dried at room temperature under atmospheric pressure to constant weight. A minimum of 0.7 mole of the isostructural pseudopolymorph was thus prepared. Upon single crystal x-ray diffraction analysis, the isostructural pseudopolymorph was characterized, identified as compound II in 10 Table 1 below. The specific conditions utilized in the preparation of that pseudopolymorph are summarized in Table 2.

### Example 2

15 **Preparation of Pseudopolymorph of Formula Ie (S=*iso*-propanol, x=1.5, y=0.5) By  
Precipitation From Isopropanol/Water  
(Method A)**

The native solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A formed as 20 described in Example 1 from 9a-DeMet (1 mole), formic acid (1.8-2.5 mole/mole 9a-DeMet) and formalin (1-1.5 mole formaldehyde/mole 9a-DeMet) was added to isopropanol (4-8 l/kg of the 9a-DeMet material). The mixture was treated in the same manner as described in Example 1, i.e. it was heated to its boiling point and stirred at that temperature for 4 hours. The reaction mixture was then cooled and activated charcoal was added thereto. After 25 stirring the mixture was filtered, and the charcoal remaining on the filter was washed with isopropanol (0.5-2.0 l/kg of the 9a-DeMet substrate). The combined isopropanol solution

(both the filtrate and the wash) was then added to the water (10-20 l/kg of the 9a-DeMet). Product crystals were thus precipitated.

The resulting mixture was alkalinized stepwise with 10% sodium hydroxide to a pH of 9.8, and then stirred at room temperature for a further 2 hours. The precipitate was a 5 crystalline, isostructural pseudopolymorph of Formula Ie, in the form of an isopropanol solvate (S = isopropanol, x=1.5 and y=0.5). The precipitate was filtered, washed with an aqueous isopropanol solution (10% V/V) and dried to constant weight at a temperature of 70°C to 80°C, under a reduced pressure of 3 to 5 kPa. A minimum of 0.7 mole of the isostructural pseudopolymorph Ie was thus prepared. Upon single crystal x-ray diffraction 10 analysis, the isostructural pseudopolymorph was characterized as identified in Table 1. The specific conditions utilized in the preparation are disclosed in Table 2.

**Example 3:**

15        **Preparation of Pseudopolymorph of Formula Id (S=n-propanol, x=1, y=0.5) By  
Precipitation From n-Propanol/Water  
(Method B)**

Crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (5g), having a water 20 content of 5.7 mole %, was dissolved with stirring in 20 ml n-propanol and heated to a temperature of 40°C to 50°C. The solution was treated with activated charcoal, filtered, and cooled to a temperature of 35°C in a 2 hour period. The mixture was seeded with 0.25 g of the isostructural pseudopolymorph of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the Formula Ie (S=n-propanol, x=1 and y=0.5), and cooled to 0°C over a 24 hour period. 25 The precipitate thus formed was the crystalline isostructural pseudopolymorph in the form of the n-propanol solvate. The precipitate was filtered, washed with cold n-propanol and dried to constant weight under a reduced pressure of 6 to 8 kPa and at a temperature of 40°C. 2.6 g of

the isostructural pseudopolymorph Id characterized as identified in Table 1 was thus produced. The conditions utilized in the preparation are disclosed in Table 2.

**Example 4:**

5

**Preparation of Pseudopolymorph of Formula Ig (S=*iso*-butanol, x= 1.25, y=0.5)  
by Precipitation From Isobutanol/Water  
(Method C)**

10 Amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (5g), having a water content of 3.8 mole %, was dissolved in 15 ml of isobutanol and heated to a temperature of 40°C. At that temperature, water was gradually added to the solution with stirring until slight turbidity formed. The solution was then gradually cooled to room temperature over 5 hours and allowed to stand at this temperature without stirring for a further 18 hours. The resulting 15 precipitate was a crystalline, isostructural pseudopolymorph of Formula Ig, in the form of an isobutanol solvate (S = isobutanol, x=1.25 and y=0.5). The precipitate was filtered, washed with a cold aqueous solution of isobutanol (10% V/V) and dried to constant weight under atmospheric pressure and room temperature. 2.2 g of the pseudopolymorph Ig was thus prepared. Upon single crystal x-ray diffraction analysis, the crystal structure characterized in 20 Table 1 was identified. The conditions of the preparative technique are disclosed in Table 2.

**Example 5:**

25

**Preparation of Pseudopolymorph of Formula Ic (S= Ethanol , x=1, y=0.5)  
By Precipitation From Ethanol/Water  
(Method D)**

9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate (5 g; purity: USP 25) was dissolved in 35 ml of 96% ethanol. The stirred solution was heated to a temperature of

30°C to 40°C, and subsequently added gradually, over a period of 2 hours, to 70 ml of water at 40°C under seeding with 50 mg of the isostructural pseudopolymorph of Formula Ia in which x=1 and y=0. The mixture was then gradually cooled to 5°C over a 24 hours period, with formation of a precipitate. The precipitate was filtered, washed with cold 96 % ethanol, 5 and dried to constant weight under atmospheric pressure and at a temperature of 0°C to 10°C. 2.0 g of the pseudopolymorph Ic was obtained. Upon single crystal x-ray diffraction analysis, the isostructural pseudopolymorph Ic characterized in Table 1 was identified. The parameters of the preparation technique are disclosed in Table 2.

10 **Examples 6-9:**

**Preparation of the Pseudopolymorphs of Formulas Ij (S=Glycerol, x=1, y=0.5), Ik (S=Glycerol, x=1. 5, y=0.5), Ib (S=Methanol, x=1.25, y=1), and Im (S=DMSO, x=1, y=0.5)**

15 Analogous to the procedures outlined in Examples 3-5, crystalline isostructural pseudopolymorphs of Formula I in the form of the glycerol solvates Ij (S = glycerol, x=1 and y=0.5) and Ik (S = glycerol x=1.5 and y=0.5), the methanol solvate Ib (S = methanol, x=1.25 and y=1), and the dimethyl sulfoxide (DMSO) solvate Im (S = DMSO, x=1 and y=0.5) were prepared. Upon single crystal x-ray diffraction analysis, the respective pseudopolymorphs Ij, 20 Ib, and Im were characterized as identified in Table 1. The preparative conditions are disclosed in Table 2.

**Example 10:**

**Preparation of the Pseudopolymorphs of Formulas Ih (S=1,2-Ethanediol, x=1, y=0.5)  
by Precipitation From 1,2-Ethanediol  
(Method E)**

5

60 ml of a native solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A in ethyl acetate, prepared as described in of WO 01/00640, was diluted with a further 40 ml of ethyl acetate. The resulting mixture was alkalized stepwise with 10 % NaOH solution to a 10 pH of 9.8, and the layers separated. The ethyl acetate layer was washed with a saturated sodium chloride solution and treated with activated charcoal. The mixture was then filtered, and the charcoal remaining on the filter was washed with ethyl acetate (5 ml). To the combined ethyl acetate solution (both the filtrate and wash), 30 ml of 1,2-ethanediol was added. The ethyl acetate was then distilled out at atmospheric pressure. The residue after 15 distillation was slowly cooled from 90 °C to 0 °C over a period of 30 hours.

The resulting precipitate was a crystalline isostructural pseudopolymorph of Formula Ih, in the form of a 1,2-ethanediol solvate (S = 1,2-ethanediol, x=1 and y=0.5). The precipitate was filtered, washed with a cold aqueous solution of 1,2-ethanediol (10 % V/V) and dried to constant weight under atmospheric pressure and at a temperature of 0 °C to 10 20 °C. 3.4 g of the pseudopolymorph Ih was thus prepared. Upon single crystal x-ray diffraction analysis, the isostructural pseudopolymorph Ih was characterized, as indicated in Table 1. Preparative conditions are summarized in Table 2.

**Example 11:****Conversion of the Pseudopolymorph II (S=Acetone, x=1, y=0.5)  
to Pseudopolymorph Ia (x=1, y=0)**

5

A native dichloromethane solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, prepared using the procedure described in U.S. Patent No. 4,474,768, was converted to a crystalline isostructural pseudopolymorph of Formula II (S = acetone, x=1 and y=0.5) using the procedures described in Examples 10 and 5 above, by methods E and D.

10 The precipitate thus formed was filtered and washed with an aqueous acetone solution (10 % V/V). Upon drying under a reduced pressure of 2 to 5 kPa and at a temperature of 70°C to 80°C, 0.6 mole of pseudopolymorph Ia (x=1, y=0) was obtained (purity: USP 25). The crystal structure of pseudopolymorph Ia was characterized as identified in Table 1. The conditions employed are summarized in Table 2.

15

**Examples 12-13:****Preparation of the Pseudopolymorphs of Formulas If (S=n-Butanol, x=1.5, y=0.5) and****Ii (S=1,3-Propanediol, x=1, y=0.5)**

A native chloroform solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, prepared according to the procedure described in U.S. Patent No. 4,517,359, was converted to the pseudopolymorph If (S = n-butanol, x=1.5, and y=0.5). A native butyl acetate solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, prepared according to the procedure disclosed in WO 99/58541, was converted to the pseudopolymorph Ii (S = 1,3-propanediol, x=1 and y=0.5).

The pseudopolymorphs were prepared by analogy to the procedures described in Examples 3, 5, 10 and 11, by methods E and B as well as E and D. Upon single crystal x-ray diffraction analysis the pseudopolymorphs If and Ii were characterized, as indicated in Table 1. The conditions utilized are summarized in Table 2.

5

**Example 14:****Conversion of the Pseudopolymorph II (S=Acetone, x=1, y=0.5)  
to Pseudopolymorph Ia (x=1, y=0)**

10 The pseudopolymorph II (S=acetone, x=1, y=0.5), obtained according to Example 1, was dried to constant weight under a reduced pressure of 0.1 kPa and at a temperature of 50°C. The resulting pseudopolymorph was characterized as Formula Ia (x=1 and y=0, Table 1). The yield was quantitative; purity: according to USP 25.

15 **Example 15:****Conversion of the Pseudopolymorph Ic (S=Ethanol, x=1, y=0.5)  
to Pseudopolymorph Ia (x=1, y=0)**

20 The pseudopolymorph Ic (S=ethanol, x=1, y=0.5), prepared as described in Example 5, was dried to constant weight under a reduced pressure of 2 kPa and at a temperature of 80 °C. The pseudopolymorph Ia obtained was identical in form and yield to that prepared in Example 14.

**Example 16:****Conversion of the Pseudopolymorph Ib (S=Methanol, x=1.25, y=1)  
to Pseudopolymorph Ia (x=1, y=0)**

5 The crystalline pseudopolymorph Ib (S=methanol, x=1.25 and y=1), obtained according to Example 8, was dried to constant weight under a reduced pressure of 2 kPa and at a temperature of 80°C. The resulting pseudopolymorph Ia, characterized in Table 1, was identical in form and yield to that obtained in Example 14.

10

**Example 17:****Conversion of the Pseudopolymorph Id (S=n-Propanol, x=1, y=0.5)  
to Pseudopolymorph Ia (x=1, y=0)**

15

The crystalline pseudopolymorph Id (S = n-propanol, x=1 and y=0.5), obtained according to Example 3, was dried to constant weight under a reduced pressure of 13 Pa and at a temperature of 80°C. The yield and purity of pseudopolymorph Ia (x=1 and y=0) thus produced were identical to those of Example 14.

20

**Example 18:****Conversion of the Pseudopolymorph Ie (S=iso-Propanol, x=1.5, y=0.5)  
to Pseudopolymorph Ia (x=1, y=0)**

25

The crystalline pseudopolymorph Ie (S=isopropanol, x=1.5 and y=0.5), obtained according to Example 2, was subjected to sublimation under a reduced pressure of 1 Pa and at

temperature of -95°C until a product of constant weight was produced. The yield and purity of the pseudopolymorph Ia (x=1 and y=0) were identical to those of Example 14.

**Example 19:**

5

**Conversion of Crude 9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A to the Pseudopolymorph Ia (x=1, y=0)**

The crude commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (100 g) 10 was suspended in 500 ml of water and acidified stepwise at room temperature during a period of 105 minutes to a pH of 5.2 using 10 % hydrochloric acid. The resulting solution was then added dropwise for about 35 minutes to 1360 ml of approximately 3 % acetone (formed by adding 1320 ml of water to 40 ml of acetone) at room temperature. To this solution, a 10% sodium hydroxide solution was added dropwise during 55 minutes at room temperature, until 15 a pH of 9.8 was obtained. The mixture was then heated to 40 °C, stirred at that temperature for 120 minutes and then cooled to 30 °C. The precipitate was a crystalline isostructural pseudopolymorph II (S = acetone, x=1, y=0.5). The precipitate was filtered, and washed twice with 30 ml of a 10% acetone solution. 234.1g of wet pseudopolymorph II (S = acetone, x=1, y=0.5) was thus obtained which, after drying to constant weight at 55°C under a vacuum 20 of 2.0 kPa, gave 93.5 g of the isostructural pseudopolymorph Ia (x=1 and y=0) of USP 25 purity (Batch 1).

Repeating this procedure twice (Batches 2 & 3) gave the pseudopolymorph Ia (x=1 and y=0) in yields of 92.5 g (Batch 2) and 93.8 g (Batch 3). Purity USP 25.

**Example 20:****Conversion of Crude 9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A to the Pseudopolymorph Ia (x=1, y=0)**

5        The crude commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A (40 g) was suspended in 200 ml of water and acidified stepwise at room temperature for about 60 minutes to a pH of 5.5. The resulting solution was added dropwise to 600 ml of a 10% acetone solution (formed by adding 60 ml of acetone to 540 ml of water) at room temperature 10 during 30 minutes. To this solution a 10% potassium carbonate solution was added dropwise at room temperature during a period of 80 minutes, until a pH of 9.8 was attained, by simultaneous seeding with 0.8 g of the pseudopolymorph II (S = acetone, x=1 and y=0.5). The mixture was then stirred at room temperature for a further 15 minutes. The resulting crystals were filtered, washed twice with 20 ml of a 10% acetone solution and dried to 15 constant weight under vacuum at 2.0 kPa and at a temperature of 75°C. 37.5g of the isostructural pseudopolymorph Ia (x=1 and y=0) was thus obtained.

**Example 21:**

20        **Conversion of Pseudopolymorph II (S=Acetone, x=1 and y =0.5) to the Pseudopolymorph Ia (x=1, y=0)**

40g of the isostructural pseudopolymorph II (S=acetone, x=1 and y=0.5) was suspended in 200 ml water and acidified with 10% acetic acid at room temperature for about 25 60 minutes to a pH of 5.5. until the pseudopolymorph II dissolved. The resulting solution was added dropwise to 600 ml of a 10% acetone solution (formed by adding 60 ml of acetone to 540 ml of water) at room temperature during 30 minutes. To this solution a 10% sodium hydroxide solution was added dropwise at room temperature during 80 minutes until a pH of

9.8 was attained, simultaneously by seeding with 0.4 g of the isostructural pseudopolymorph II (S=acetone, x=1, y=0.5). The mixture was then stirred at room temperature for a further 15 minutes. The resulting crystals were filtered, washed twice with 20 ml of a 10% acetone solution and dried to constant weight under a vacuum of 2.0 kPa at 55 °C. 35.5g of the 5 isostructural pseudopolymorph Ia (x=1 and y=0) was thus obtained.

**Example 22:**

**Reprecipitation of Pseudopolymorph Im (S=DMSO, x=1 and y=0.5).**

10 2.0 g of the isostructural pseudopolymorph Im (S = DMSO, x=1 and y=0.5), obtained as described in Example 9, was dissolved in 10 ml of DMSO at a temperature of 50°C. Water was added dropwise to the solution at that temperature until it turned slightly turbid. The mixture was then cooled to room temperature over a two hour period, and kept at this temperature for a further 72 hours. The precipitated crystalline isostructural 15 pseudopolymorph Im (S=DMSO, x=1 and y=0.5) was filtered, washed with cold water and dried to constant weight at atmospheric pressure and a temperature of 25°C. 1.1 g of the recrystallized pseudopolymorph Im (S=DMSO, x=1, y=0.5) was thus obtained.

TABLE 1 : ESSENTIAL CRYSTALLOGRAPHIC DATA OF ISOSTRUCTURAL  
9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A PSEUDOPOLYMORPHS OF THE INVENTION

Unit Cell Parameters	Ia (x=1, y=0)	Ib (S=MeOH, x=1.25, y=1)	Ic (S=EtOH, x=1, y=0.5)	Id (S=n-PrOH, x=1, y=0.5)	Ie (S=i-PrOH, x=1.5, y=0.5)	If (S=n-BuOH, x=1.5, y=0.5)	Ig (S=i-BuOH, x=1.25, y=0.5)	Ih (S=1,2- ethanediol, x=1, y=0.5)
295 K a/Å	16.368(5) <sup>1</sup>	16.546(3) <sup>1</sup>		16.32 (2) <sup>1</sup>	16.29410(10) <sup>1</sup>		16.166(8) <sup>1</sup>	16.232(15) <sup>1</sup>
b/Å	16.301(3)	16.185(6)		16.344(16)	16.24440(10)		16.123(4)	16.213(10)
c/Å	18.408(5)	18.511(7)		18.610(18)	18.80600(10)		18.591(14)	18.531(9)
β <sup>2</sup>	110.04(2)	110.53(3)		108.88(9)	108.5701(3)		107.68(14)	109.63(3)
V/Å <sup>3</sup>	4614.151	4642.273		4698.005	4718.554		4616.769	4593.361
100°K a/Å		16.3506(2) <sup>1</sup>	16.1400(10) <sup>1</sup>	16.22990(10) <sup>1</sup>	16.1580(10) <sup>1</sup>	16.11940(10) <sup>1</sup>	16.0909(2) <sup>1</sup>	
b/Å		16.09370(10)	16.1530(10)		16.05490(10)	16.0190(10)	15.97760(10)	16.0674(2)
c/Å		18.27800(10)	18.2640(10)		18.38540(10)	18.4570(10)	18.5545(2)	18.3287(2)
β <sup>2</sup>		109.4070(7)	109.590(10)		108.7563(5)	108.866(10)	107.8143(6)	109.1199(8)
V/Å <sup>3</sup>		4536.426	4485.977		4536.263	4520.668	4549.575	4477.274

<sup>1</sup> Data in parentheses indicate the statistical variation of the last digit of the reported parameter, e.g., the range of crystal axis a of Compound 1a was 16.363 to 16.373

<sup>2</sup> α and β are 90° in each instance.

TABLE 1 (Contd.)

Unit Parameters	Cell a/Å	II (S=1,3-propanediol, x=1; y=0,5)	II (S=glycerol, x=1; y=0,5)	II (S=glycerol, x=1,5; y=0,5)	II (S=acetone, x=1; y=0,5)	II (S=DMSO, x=1; y=0,5)	9-Deoxy-9a-aza-9a-methyl-9a- homooxythromycin A dihydrate <sup>3</sup>
295K	16.001(6) <sup>1</sup>	16.20(4) <sup>1</sup>	16.303(6) <sup>1</sup>	16.370(6) <sup>1</sup>	16.349(3) <sup>1</sup>	17.860	
b/Å	16.21(2)	16.253(13)	16.304(4)	16.235(7)	16.304(3)	16.889	
c/Å	18.497(11)	18.613(10)	18.725(13)	18.538(7)	18.401(3)	14.752	
$\beta/^\circ$	109.20(6)	109.30(5)	108.968(15)	109.09(3)	108.948(12)	90	
V/Å <sup>3</sup>	4530.817	4625.358	4706.922	4655.844	4639.085	4449.757	
100K	15.9690(2) <sup>1</sup>	16.0620(3) <sup>1</sup>	16.1060(10) <sup>1</sup>	16.1220(10)	16.24530(20) <sup>1</sup>		
b/Å	15.9840(2)	16.0171(3)	16.1220(10)		16.14140(20)		
c/Å	18.5610(2)	18.5618(3)	18.4760(10)		18.16580(20)		
$\beta/^\circ$	108.2430(8)	108.5100(9)	109.1290(10)		108.7695(7)		
V/Å <sup>3</sup>	4499.540	4529.142	4532.593		4510.208		

<sup>3</sup> Coded GEGLAD in Cambridge Crystallographic Database; Orthorhombic space group P21 2,2,1.

TABLE 2: CONDITIONS FOR PREPARATION OF ISOSTRUCTURAL  
9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A PSEUDOPOLYMORPHS OF THE INVENTION

Example	Starting Material	Solvent	Method	Dissolution Temperature °C	Crystallization Temperature °C	Drying Temperature °C/CPa	No.	Fig. No.
1	9a-DeMet <sup>1</sup>	Acetone	A	50 to 60	room	20 to 25/-100	I	13
2	9a-DeMet <sup>1</sup>	isop-ROH	A	70 to 80	room	40/6 to 8	Ie	6
3	Crude	n-PrOH	B	40 to 50	50 to 0	40/6 to 8	Id	5
4	Amorphous	iso-BuOH	C	40	40 to 25	20 to 25/-100	Ig	8
5	Dihydrate (USP 25)	Ethanol	D	30 to 40	40 to 5	0 to 10/-100	Ic	4
6	Dihydrate (USP 25)	2-BuOH/glycerol	B	50	50 to 25	20 to 25/-100	Ik	12
7	Crude	tert-BuOH/glycerol	C	40	40 to 25	0 to 10/-100	Ij	11
8	Unstable monohydrate	Methanol	C	20 to 30	30 to -5	20 to 25/-100	Ib	3
9	Crude	Dimethyl sulfoxide	D	30 to 40	40 to 25	20 to 25/3 to 5	Im	14
10	Sol/EtOAc (WO 01/00640)	1,2-Ethanediol	E+B	90	90 to 0	0 to 10/-100	Ih	9
11	Sol/CH <sub>2</sub> Cl <sub>2</sub> (US 4474768)	Acetone	E+D	50 to 60	room	80/2 to 5	Ia	2
12	Sol/CHCl <sub>3</sub> (US 4517359)	n-BuOH	E+B	50	50 to 0	0 to 10/-100	If	7
13	Sol/n-BuOAc (WO 99/58541)	1,3-Propanediol	E+D	80	40	0 to 10/-100	Ii	10

1. 9a-DeMet = 9-Deoxo-9a-aza-9a-homoerythromycin A

**TABLE 3: FORMATION OF ISOSTRUCTURAL  
9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A  
PSEUDOPOLYMORPH Ia (x=1, y=0)**

5

Example	Starting Material	Method	Drying Temperature / Pressure
14	Pseudopolymorph II (S=acetone, x=1, y=0.5)	Drying	50°C / 0.1 kPa
15	Pseudopolymorph Ic (S=Ethanol, x=1, y=0.5)	Drying	80°C / 2 kPa
16	Pseudopolymorph Ib (S=Methanol, x=1.25, y=1)	Drying	80°C / 2 kPa
17	Pseudopolymorph Id (S=n-Propanol, x=1, y=0.5)	Drying	80°C / 13 Pa
18	Pseudopolymorph Ie (S=Isopropanol, x=1.5, y=0.5)	Sublimation	-95°C / 1 Pa
19	Crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A <sup>1</sup>	Drying In Situ Formed Wet Pseudopolymorph II	55°C / 2.0 kPa
20	Crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A <sup>1</sup>	Drying In Situ Formed Wet Pseudopolymorph II <sup>2</sup>	75°C / 2.0 kPa
21	Pseudopolymorph II (S=acetone, x=1, y=0.5) <sup>2</sup>	Drying	55°C / 2.0 kPa

10

1. Pseudopolymorph II (S=Acetone, x=1, y=0.5) prepared from crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A and wet solvate dried in situ
2. Pseudopolymorph II (S=Acetone, x=1, y=0.5) crystallized using crystal seeding technique

#### Formulations of the Pseudopolymorphs

**Example 23:**

**Tablet Formulations**

15

9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph formulations were prepared by granulating isostructural pseudopolymorph (97%) of Examples 11 and 14-21 (x=1 and y=0 with starch, microcrystalline cellulose and croscarmellose sodium by standard granulation techniques. The dried granulates were homogenized with magnesium

stearate, and tabletted using standard tabletting machines. Tablet cores were coated with a hydroxypropyl methylcellulose (HPMC) coating. The quantities of ingredients for 150, 200, 250, 300, 500 and 600 mg tablets are given in Table 4.

5 **Table 4 : TABLET FORMULATIONS OF 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHRAMYCIN A MONOHYDRATE PSEUDOPOLYMORPH (x=1, y=0)**

Formulation Component / Dose:	150 mg	200 mg	250 mg	300 mg	500 mg	600 mg
Isostructural pseudopolymorph of Formula I (x=1, y=0) (97%)	158	210	263	316	526	632
Starch	16	20	25	30	50	60
Microcrystalline cellulose	85	115	140	170	280	340
Croscarmellose sodium	5	7	9	10	18	21
Mg-stearate	2	3	4	5	9	10
HPMC (hydroxypropyl methylcellulose)	8	11	14	16	27	32

10

**Example 24:**

**Topical Formulations**

15

Water, co-solvents (glycerol, polyethylene glycol), preservatives (methyl and propylparaben), stabilizer and gelling polymer are homogenized by standard technique to form an aqueous phase.

20 The isostructural pseudopolymorph Ia (x=1 and y=0) was added to such an aqueous phase and it was dispersed/dissolved. Oily components (such as liquid paraffin and cetyl alcohol), with the addition of emulsifier, were melted, and after being cooled, were mixed with the previously prepared aqueous phase. The final homogenization was carried out under reduced pressure. Odorant may be added to the last phase, i.e. homogeneous gel, and

optionally its pH may be adjusted. A typical pseudopolymorph-containing formulation thus prepared is given in Table 5.

TABLE 5

5 **TOPICAL FORMULATION CONTAINING ISOSTRUCTURAL 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A PSEUDOPOLYMORPH Ia**

Component	Dose (mg/ g)	Role
Isostructural 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A Ia (x=1, y=0)	100	active substance
Glycerol	100.00	co-solvent
Isopropanol	400.00	co-solvent
PEG	60.00	co-solvent
Carbomer	15.00	gelling polymer
Citric acid	qs	pH adjustor
Polysorbate 40	10.00	emulsifier
Methylparaben	0.70	preservative
Propylparaben	0.30	preservative
Disodium-EDTA	0.5	stabilizer
Liquid paraffin	25.00	oily component
Cetyl alcohol	25.00	oily component
Odorant	qs	
Water	up to 1 g	

In these mixtures, a wide range of concentrations of the isostructural 10 pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A can be utilized; a preservative may also be incorporated in the preparation depending on the dosage form (i.e., multidose or monodose).

**Superior Properties of the Isostructural Pseudopolymorph of the Invention**

15 **Example 25:**

**Dissolution Profiles Of The New Pseudopolymorph Of The Invention vs. Commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A Dihydrate**

In order to compare the behavior *in vitro* of the 9-deoxo-9a-aza-9a-methyl-9a-20 homoerythromycin A pseudopolymorph Ia of the invention with the commercial 9-deoxo-9a-

aza-9a-methyl-9a-homoerythromycin A dihydrate product, dissolution profiles have been determined at pH 3 and pH 6, at 37°C. For comparison, 3 batches of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia from Example 19 above were used. The comparative dissolution profiles were determined by USP Method 2, PharmaTest 5 Dissolution Tester, PTW SII; the content of dissolved 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A was measured by HPLC. The data thus obtained are set forth in Table 6 below, and plotted in Figures 17 and 18.

TABLE 6

10 **PERCENT OF 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A  
PSEUDOPOLYMORPH Ia AND COMMERCIAL 9-DEOXO-9a-AZA-9a-METHYL-  
9a-HOMOERYTHROMYCIN A DIHYDRATE PRODUCT DISSOLVED**

Time	Commercial 9-deoxo-9a- aza-9a- methyl-9a- homoerythro- mycin A Dihydrate		9-deoxo-9a-aza- 9a-methyl-9a- homoerythromyci n A Pseudopolymorph Ia (Example 19, Batch 1)		9-deoxo-9a-aza- 9a-methyl-9a- homoerythromyci n A Pseudopolymorph Ia (Example 19 Batch 2)		9-deoxo-9a-aza- 9a-methyl-9a- homoerythromyci n A Pseudopolymorph Ia (Example 19, Batch 3)	
Minutes	pH 3	pH 6	pH 3	pH 6	pH 3	pH 6	pH 3	pH 6
5	3.9	14.5	25.1	67.0	18.5	71.7	21.1	70.2
10	8.1	27.3	37.1	73.2	30.7	81.4	32.4	77.3
20	14.6	44.2	45.8	76.7	45.1	81.6	43.3	77
45	26.7	69.1	55.5	76.7	60.9	80.4	56	77.6
60	33.3	73.7	58.3	74.5	64.8	79.9	61.1	78
90	39.1	75.0	62.9	75.8	70	80	64.7	79.2

15 In addition to the above data, the intrinsic dissolution rates (IDR's) for the new pseudopolymorph of the invention and the commercial dihydrate, at pH 3 and pH 6 and 37°C, were determined by Intrinsic Dissolution Tester, Van Kel Type. The IDR for the new pseudopolymorph was about  $2.5-2.8 \text{ mg min}^{-1} \text{ cm}^{-2}$ , about 40 to 50% higher than the IDR of

the prior art 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate (about 1.8 mg  $\text{min}^{-1}\text{cm}^{-2}$ ).

### Example 26:

# Comparison of Dissolution Profiles of Three Batches of The New Pseudopolymorph Of The Invention And Commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A Dihydrate.

10 In order to further assess the data from Table 6, similarity factors (f2) were calculated according to the method described in *Note for Guidance on the Investigation of Bioavailability and Bioequivalence (EMEA, December 1998, London)* for the dissolution profiles of the two species (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, pseudopolymorph Ia of the present invention, and commercial 9-deoxo-9a-aza-9a-methyl-9a-  
15 homoerythromycin A dihydrate).

A similarity factor (f2) of between 50 and 100 suggests that two dissolution profiles compared are similar and suggests that they have similar bioavailability. On the other hand, f2 values below 50 indicate significant differences in two dissolution profiles and hence in their relative bioavailability. A comparison of the calculated f2 values for the respective pairs of the three batches of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia ( $x = 1, y = 0$ ) prepared according to Example 19 are given in Table 7. Also given is a comparison of the f2 values for each batch of Example 19 as compared with the commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate product.

**TABLE 7: CALCULATED SIMILARITY FACTORS FOR THE  
9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A  
PSEUDOPOLYMORPH Ia OF EXAMPLE 19  
AND THE COMMERCIAL 9-DEOXO-9a-AZA-9a-METHYL-9a-  
HOMOERYTHROMYCIN A DIHYDRATE PRODUCT**

5

Similarity factor (f2)	f2 Value Comparison Between Batches of 9-deoxo-9a-aza-9a-methyl-9a- homoerythromycin A Pseudopolymorph Ia (x=1, y=0) of Example 19			f2 Value Comparison Between Batches of 9-deoxo-9a-aza-9a-methyl-9a- homoerythromycin A Pseudopolymorph Ia(x=1, y=0) of Example 19 and the Commercial 9-deoxo-9a-aza-9a-methyl- 9a-homoerythromycin A Dihydrate		
	Batch 1 vs. Batch 2	Batch 1 vs. Batch 3	Batch 2 vs. Batch 3	Dihydrate vs. Batch 1	Dihydrate vs. Batch 2	Dihydrate vs. Batch 3
pH = 3	61.3	74.7	71.3	28.6	27.5	29.4
pH = 6	63.1	75.4	75.3	25	22.2	23.7

According to Table 7, Batches 1, 2, and 3 of the 9-deoxo-9a-aza-9a-methyl-9a-  
10 homoerythromycin A pseudopolymorph Ia (x=1, y=0) of Example 19 have similar  
dissolution profiles (and hence bioavailability), whereas the dissolution profiles of the  
dihydrate relative to each batch of the new pseudopolymorph of the invention are dissimilar  
(and hence the bioavailability would be expected to significantly differ). Given these  
properties, it would be expected that the pseudopolymorphs of the invention would have  
15 consistent, superior release characteristics, particularly with respect to immediate or  
controlled release formulations .

**Example 27:**

**Solid State Stability Of New Pseudopolymorph Ia Of The Invention**

20 The solid state stability of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A  
pseudopolymorph Ia (x=1, y=0) was determined by measuring the solid state x-ray powder

diffraction pattern for this material at four different percent relative humidities (% RH), ranging from 5% RH to 75 % RH, and at five different temperatures, increasing from 30°C to 75°C using Philips X'PertPRO powder X-ray diffractometer equipped with Anton Paar TTK-100 humidity camera used for non-ambient data collection. The results are shown in Figure

5 19. As illustrated, no phase-transitions occur, i.e., there is no interconversion of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia ( $x=1$ ,  $y=0$ ) to any other form, as either the temperature increases or the relative humidity increases.

**Example 28:**

10 ***In Vivo* Pharmacokinetic Profiles Of New Pseudopolymorph Ia Of The Invention vs. Commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A Dihydrate.**

In order to compare the behavior *in vivo* of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia of the invention with commercial 9-deoxo-9a-15 aza-9a-methyl-9a-homoerythromycin A dihydrate product, plasma and whole blood concentration time curves have been determined in rats after *per os* administration at a concentration of 50 mg/kg body weight. 32 animals were studied using a cross-over experimental design experiment. A non-compartmental analysis was used to determine the concentrations of the respective materials in whole blood and plasma as a function of time.

15 The data thus obtained are set forth in Figures 20 and 21.

The pharmacokinetic parameters for the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia of the invention and the commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate product in whole blood and in plasma in rats following a *per os* dose of 50 mg/kg body weight are set forth in Table 8 below.

TABLE 8

**IN VIVO PHARMACOKINETIC PARAMETERS FOR 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A PSEUDOPOLYMORPH IA AND COMMERCIAL 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A DIHYDRATE**

5

	9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate		9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia	
	Whole Blood	Plasma	Whole Blood	Plasma
C <sub>max</sub> (ng/ml)	2569.0 ± 606.0	734.5 ± 307.2	5061.0 ± 1804.4	1005.5 ± 131.0
T <sub>max</sub> (hr)	2	2	2	2
AUC <sub>(0-12)</sub> (ng·hr/ml)	16721.1	3997.9	21203.9	5147.7
AUC <sub>(0-24)</sub> (ng·hr/ml)	24442.8	5755.6	29272.6	6853.2
AUC <sub>(0-48)</sub> (ng·hr/ml)	31696.6		35659.0	

As indicated in Table 8, higher concentrations of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia of the invention as compared with the commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate product are observed in both whole blood and plasma following *per os* administration in rats. The greatest concentration difference between the two 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A products is observed after 2 hours (T<sub>max</sub>).

Higher AUC values were particularly observed for the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia during the first 12 hours following administration. The calculated AUC value for the first 0-12 hours, AUC<sub>(0-12)</sub>, is surprisingly approximately 20% higher for the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia relative to the commercial 9-deoxo-9a-aza-9a-methyl-9a-

homoerythromycin A dihydrate product in both whole blood and plasma.

These results suggest faster absorption, higher bioavailability and more rapid distribution of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ia into cells and/or tissues relative to the commercial 9-deoxo-9a-aza-9a-methyl-9a-  
5 homoerythromycin A dihydrate product.

**Example 29:**

**Dissolution Profiles Of The New Pseudopolymorph Ik (S = glycerol; x = 1.5, y = 0.5) Of  
The Invention vs. Commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A  
10 Dihydrate**

In order to compare the behavior *in vitro* of the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ik of the invention with the commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate product, dissolution profiles have been  
15 determined at pH 6, at 37°C. For comparison, 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph Ik from Example 6 above was used. The comparative dissolution profiles were determined by USP Method 2, PharmaTest Dissolution Tester, PTW SII; the content of dissolved 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A was measured by HPLC. The data thus obtained are set forth in Table 9 below, and plotted  
20 in Figure 22.


TABLE 9

5 PERCENT OF 9-DEOXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A  
PSEUDOPOLYMORPH Ik AND COMMERCIAL 9-DEOXO-9a-AZA-9a-METHYL-  
9a-HOMOERYTHROMYCIN A DIHYDRATE PRODUCT DISSOLVED

Time	Commercial 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A Dihydrate	9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A Pseudopolymorph Ik (Example 6)
Minutes	pH 6 (37°C)	pH 6 (37°C)
5	14.5	99.8
10	27.3	99.9
20	44.2	97.1
45	69.1	97.6

What is claimed is:

1. A process for the preparation of a substantially pure isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A having the Formula I:



wherein

S is an organic solvent which is at least partially miscible with water,

x is 1, 1.25, 1.5 or 2,

y is 0, 0.5, or 1,

the pseudopolymorph being characterized by the monoclinic space group  $P2_1$  and average unit cell parameters comprising:

crystal axis lengths of  $a = 15.5 - 17.0 \text{ \AA}$ ,  $b = 15.5 - 17.0 \text{ \AA}$  and  $c = 17.5 - 19.5 \text{ \AA}$ , and

angles between the crystal axes of  $\alpha = \gamma = 90^\circ$  and  $\beta = 106^\circ - 112^\circ$ ;

which process comprises:

(a) dissolving a 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material in (1) an organic solvent which is at least partially water-miscible, (2) a mixture of such organic solvents, (3) a mixture of the organic solvent and water or (4) a mixture of water and at least one mineral or organic acid;

(b) crystallizing the isostructural pseudopolymorph from the solution;

(c) isolating the isostructural pseudopolymorph; and

(d) transforming the isostructural pseudopolymorph of Formula I to a stable isostructural pseudopolymorph of Formula Ia wherein  $x=1$  and  $y=0$ .

2. The process of claim 1, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material dissolved in step (a) is (i) a crystalline 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, whether in crude or purified form, (ii) an amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, whether in crude or purified form, (iii) solvates or hydrates of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, whether in crude or purified form, or (iv) a native solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A formed during the final step of its syntheses from any of its last intermediates.

3. The process of claim 2, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material utilized to prepare novel pseudopolymorphs, dissolved in step (a) is a crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A in any of its known forms and having less than pharmaceutically acceptable purity.

4. The process of claim 2, wherein the native solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A utilized to prepare novel pseudopolymorphs, dissolved in step (a) is a solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, formed in the native solution during the final step of its syntheses, from any of its last intermediates.

5. The process of claim 2, wherein the native solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A utilized to prepare novel pseudopolymorphs, dissolved in step (a) is a solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, formed in the native solution during the final step of its syntheses, from 9-deoxo-9a-aza-9a-homoerythromycin A as its last intermediate.
6. The process of claim 2, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dissolved in step (a) is in the form of a dispersion of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A and the 9-deoxo-9a-aza-9a-homoerythromycin A intermediate in the native solution used in the final stage of the synthesis of crude 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A.
7. The process of claim 4, wherein the solvent in the native solution is selected from the group consisting of one or more haloalkanes having 1 or 2 carbon atoms, esters of acetic acid with a C<sub>2</sub>-C<sub>4</sub> lower alkyl group, monohydric C<sub>2</sub>-C<sub>4</sub> alkanols, C<sub>1</sub>-C<sub>4</sub> ketones, aromatic or substituted aromatic compounds, or a mixture thereof.
8. The process of claim 2, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dissolved in step (a) is amorphous 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A; a crystalline anhydrous, monohydrate, dihydrate or solvate form of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A; or an isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of Formula I.
9. The process of claim 2, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dissolved in step (a) is of pharmaceutically acceptable purity.

10. The process of claim 1, wherein step (a) is conducted at a temperature of from about 20 °C to about 100 °C.
11. The process of claim 1, wherein the organic solvent in which the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A is dissolved in step (a) is one or more lower aliphatic straight or branched-chain alkanols, cycloalkanols, arylalkanols, diols, triols, ethers, ketones, esters, amides, ureas, nitriles, sulfoxides or sulfones; one or more heterocyclic amines or lactams; or mixtures thereof.
12. The process of claim 1, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph is crystallized in step (b) by controlled cooling of the solution containing the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A at temperatures of from about 80°C to about -10°C.
13. The process of claim 1, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph is crystallized in step (b) isothermally at a temperature of from about 25°C to about 60°C, by standing or mixing the solution formed in step (a) in an organic solvent which is at least partially water-miscible, at said isothermal conditions.
14. The process of claim 1, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph is crystallized in step (b) isothermally at a temperature of from about 25°C to about 60°C, by saturating the solution formed in step (a) in an organic solvent which is at least partially water-miscible, with water until the solution turns slightly turbid.

15. The process of claim 1, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph is crystallized in step (b) by neutralizing the aqueous acidic solution of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A formed in step (a), at temperatures of from about 80 °C to about -10 °C.
16. The process of claim 1 wherein the isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of Formula I is added to the solution in step (b) in an amount of from about 0.01 to about 5.0 weight %, based on the amount of the starting 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A material, to seed crystallization of the isostructural pseudopolymorph therein.
17. The process of claim 1, wherein the 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A pseudopolymorph of Formula I is isolated in step (c) by:
  - (i) separating the pseudopolymorph from the solution formed in step (a);
  - (ii) washing the resulting product with solvents (1), (2) or (3) used in step (a), at temperatures of from about - 10 °C to about 40°C; and
  - (iii) drying the washed product under atmospheric pressure at temperatures of from about 20°C to about 120°C, or under reduced pressures of from about 2 kPa to about 80 kPa.

18. The process of claim 1, wherein the pseudopolymorph of Formula I is transformed in step (d) to the stable isostructural pseudopolymorph of Formula Ia wherein  $x=1$  and  $y=0$  by lyophilizing or further drying the pseudopolymorph at atmospheric pressure or at reduced pressures of from about 0.01 to about 80 kPa and temperatures of from about -100°C to about 120°C.

19. The process of claim 1, wherein the pseudopolymorph of Formula I (Ia:  $x=1$ ,  $y=0$ ) formed in step (d) is characterized by monoclinic space group  $P2_1$ , having unit cell parameters at a temperature of 22 °C of

$a = 16.368(5)$  Å,

$b = 16.301(3)$  Å,

$c = 18.408(5)$  Å,

$\alpha = \gamma = 90^\circ$ , and

$\beta = 110.04(2)^\circ$ .

20. The substantially pure isostructural pseudopolymorph having Formula I prepared by the process of claim 1.

21. The substantially pure isostructural pseudopolymorph having Formula Ia, prepared by the process of claim 1, characterized by monoclinic space group  $P2_1$  and having average unit cell parameters at a temperature of 22 °C of

$a = 16.368(5)$  Å,


$b = 16.301(3)$  Å,

$c = 18.408(5)$  Å,

$\alpha = \gamma = 90^\circ$ , and

$\beta = 110.04(2)^\circ$ .

22. A substantially pure isostructural pseudopolymorph of 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A, having the Formula I:



wherein

S is an organic solvent which is at least partially miscible with water,

x is 1, 1.25, 1.5 or 2,

y is 0, 0.5, or 1,

the pseudopolymorph being characterized by the monoclinic space group  $P2_1$  and

average unit cell parameters of

crystal axis lengths of  $a = 15.5 - 17.0 \text{ \AA}$ ,  $b = 15.5 - 17.0 \text{ \AA}$  and  $c = 17.5 - 19.5 \text{ \AA}$ , and

angles between the crystal axes of  $\alpha = \gamma = 90^\circ$  and  $\beta = 106^\circ - 112^\circ$ .

23. The substantially pure isostructural pseudopolymorph of claim 22, selected from the group of pseudopolymorphs (Ia) - (Im) set forth below, wherein x, y and S in Formula I, and the average unit cell parameters, i.e., crystal axis lengths a, b and c

and angles  $\alpha$ ,  $\beta$  and  $\gamma$  between the crystal axes, of the crystal structures, are:

(Ia)  $x=1$ ,  $y=0$  and, at 22°C:

$$a = 16.368(5) \text{ \AA},$$

$$b = 16.301(3) \text{ \AA},$$

$$c = 18.408(5) \text{ \AA},$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 110.04(2)^\circ.$$

(Ib)  $x=1.25$ ,  $y=1$  (S=MeOH) and, at 22°C:

$$a = 16.546(3) \text{ \AA}$$

$$b = 16.185(6) \text{ \AA}$$

$$c = 18.511(7) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 110.53(3)^\circ$$

(Ic)  $x = 1$ ,  $y = 0.5$  (S = EtOH) and, at - 173°C:

$$a = 16.1400(10) \text{ \AA}$$

$$b = 16.1530(10) \text{ \AA}$$

$$c = 18.2640(10) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 109.590(10)^\circ$$

(Id)  $x = 1$ ,  $y = 0.5$  (S=n-PrOH) and, at 22°C:

$$a = 16.32(2) \text{ \AA}$$

$$b = 16.344(16) \text{ \AA}$$

$$c = 18.610(18) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 108.88(9)^\circ$$

(Ie)  $x = 1.5 = y = 0.5$  (S=i-PrOH) and at 22°C:

$$a = 16.29410(10) \text{ \AA}$$

$$b = 16.24440(10) \text{ \AA}$$

$$c = 18.80600(10) \text{ \AA}$$

$\alpha = \gamma = 90^\circ$ , and

$$\beta = 108.5701(3)^\circ$$

(If)  $x = 1.5 y = 0.5$  (S=n-BuOH) and, at -173°C:

$$a = 16.1580(10) \text{ \AA}$$

$$b = 16.0190(10) \text{ \AA}$$

$$c = 18.4570(10) \text{ \AA}$$

$\alpha = \gamma = 90^\circ$ , and

$$\beta = 108.866(10)^\circ$$

(Ig)  $x = 1.25 y = 0.5$  (S=i-BuOH) and, at 22°C:

$$a = 16.166(8) \text{ \AA}$$

$$b = 16.123(4) \text{ \AA}$$

$$c = 18.591(14) \text{ \AA}$$

$\alpha = \gamma = 90^\circ$ , and

$$\beta = 107.68(14)^\circ$$

(Ih)  $x = 1, y = 0.5$  (S=1,2-ethanediol) and, at 22°C:

$$a = 16.232(15) \text{ \AA}$$

$$b = 16.213(10) \text{ \AA}$$

$$c = 18.531(9) \text{ \AA}$$

$\alpha = \gamma = 90^\circ$ , and

$$\beta = 109.63(3)^\circ$$

(ii)  $x=1, y=0.5$  (S=1,3-propanediol) and, at 22°C:

$a = 16.001(6)$  Å

$b = 16.21(2)$  Å

$c = 18.497(11)$  Å

$\alpha = \gamma = 90^\circ$ , and

$\beta = 109.20(6)^\circ$

(Ij)  $x = 1, y=0.5$  (S=glycerol) and, at 22°C:

$a = 16.20(4)$  Å

$b = 16.253(13)$  Å

$c = 18.613(10)$  Å

$\alpha = \gamma = 90^\circ$ , and

$\beta = 109.30(5)^\circ$

(Ik)  $x = 1.5, y = 0.5$  (S=glycerol) and, at 22°

$a = 16.303(6)$  Å

$b = 16.304(4)$  Å

$c = 18.725(13)$  Å

$\alpha = \gamma = 90^\circ$ , and

$\beta = 108.968(15)^\circ$

(Il)  $x = 1.5, y=0.5$  (S=acetone) and, at 22°C;

$a = 16.370(6)$  Å

$b = 16.235(7)$  Å

$c = 18.538(7)$  Å

$\alpha = \gamma = 90^\circ$ , and

$\beta = 109.09(3)^\circ$

(Im)  $x = 1, y=0.5$  (S=DMSO) and, at 22° C:

$a = 16.349(3) \text{ \AA}$

$b = 16.304(3) \text{ \AA}$

$c = 18.401(3)$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 108.948(12)^\circ$ .

24. The substantially pure isostructural pseudopolymorph of claim 22, possessing the structural parameters:

$x = 1, y = 0$ ,

and characterized by monoclinic space group  $P2_1$  and unit cell parameters, i.e., crystal axis lengths  $a$ ,  $b$  and  $c$  and angles  $\alpha$ ,  $\beta$  and  $\delta$  between the crystal axes, at a temperature of 22 °C, of

$a = 16.368(5) \text{ \AA}$ ,

$b = 16.301(3) \text{ \AA}$ ,


$c = 18.408(5) \text{ \AA}$ ,

$\alpha = \gamma = 90^\circ$ , and

$\beta = 110.04(2)^\circ$ .

25. A pharmaceutical composition comprising a substantially pure isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A having the

Formula I:



wherein

S is an organic solvent which is at least partially miscible with water,

x is 1, 1.25, 1.5 or 2,

y is 0, 0.5, or 1,

the pseudopolymorph being characterized by the monoclinic space group P2<sub>1</sub> and

average unit cell parameters of

crystal axis lengths of a = 15.5 - 17.0 Å, b = 15.5 - 17.0 Å and c = 17.5 - 19.5 Å, and

angles between the crystal axes of  $\alpha = \gamma = 90^\circ$  and  $\beta = 106^\circ - 112^\circ$

in combination with a pharmaceutically acceptable carrier.

26. The pharmaceutical composition of claim 25 wherein the substantially pure

isostructural pseudopolymorph having Formula I is selected from the group of

pseudopolymorphs (Ia)-(Im) set forth below, wherein x, y and S in Formula I, and

the average unit cell parameters, i.e., crystal axis lengths a, b and c and angles  $\alpha$ ,  $\beta$

and  $\gamma$  between the crystal axes, of the crystal structures, are:

(Ia)  $x=1, y=0$  and, at 22°C:

$$a = 16.368(5) \text{ \AA},$$

$$b = 16.301(3) \text{ \AA},$$

$$c = 18.408(5) \text{ \AA},$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 110.04(2)^\circ.$$

(Ib)  $x=1.25, y=1$  (S=MeOH) and, at 22°C:

$$a = 16.546(3) \text{ \AA}$$

$$b = 16.185(6) \text{ \AA}$$

$$c = 18.511(7) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 110.53(3)^\circ$$

(Ic)  $x = 1, y = 0.5$  (S = EtOH) and, at - 173°C:

$$a = 16.1400(10) \text{ \AA}$$

$$b = 16.1530(10) \text{ \AA}$$

$$c = 18.2640(10) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 109.590(10)^\circ$$

(Id)  $x = 1, y = 0.5$  (S=n-PrOH) and, at 22°C:

$$a = 16.32(2) \text{ \AA}$$

$$b = 16.344(16) \text{ \AA}$$

$$c = 18.610(18) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 108.88(9)^\circ$$

(Ie)  $x = 1.5 = y = 0.5$  (S=i-PrOH) and at 22°C:

$$a = 16.29410(10) \text{ \AA}$$

$$b = 16.24440(10) \text{ \AA}$$

$$c = 18.80600(10) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 108.5701(3)^\circ$$

(If)  $x = 1.5 y = 0.5$  (S=n-BuOH) and, at -173°C:

$$a = 16.1580(10) \text{ \AA}$$

$$b = 16.0190(10) \text{ \AA}$$

$$c = 18.4570(10) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 108.866(10)^\circ$$

(Ig)  $x = 1.25 y = 0.5$  (S=i-BuOH) and, at 22°C:

$$a = 16.166(8) \text{ \AA}$$

$$b = 16.123(4) \text{ \AA}$$

$$c = 18.591(14) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 107.68(14)^\circ$$

(Ih)  $x = 1, y = 0.5$  (S=1,2-ethanediol) and, at 22°C:

$$a = 16.232(15) \text{ \AA}$$

$$b = 16.213(10) \text{ \AA}$$

$$c = 18.531(9) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 109.63(3)^\circ$$

(Ii) x=1, y=0.5 (S=1,3-propanediol) and, at 22°C:

a = 16.001(6) Å

b = 16.21(2) Å

c = 18.497(11) Å

α = γ = 90°, and

β = 109.20(6)°

(Ij) x = 1, y=0.5 (S=glycerol) and, at 22°C:

a = 16.20(4) Å

b = 16.253(13) Å

c = 18.613(10) Å

α = γ = 90°, and

β = 109.30(5)°

(Ik) x = 1.5, y = 0.5 (S=glycerol) and, at 22°

a = 16.303(6) Å

b = 16.304(4) Å

c = 18.725(13) Å

α = γ = 90°, and

β = 108.968(15)°

(Il) x = 1.5, y=0.5 (S=acetone) and, at 22°C;

a = 16.370(6) Å

b = 16.235(7) Å

c = 18.538(7) Å

α = γ = 90°, and

β = 109.09(3)°

(Im) x = 1, y=0.5 (S=DMSO) and, at 22° C:

$a = 16.349(3) \text{ \AA}$

$b = 16.304(3) \text{ \AA}$

$c = 18.401(3)$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 108.948(12)^\circ$ .

27. The pharmaceutical composition of claim 25, wherein the substantially pure isostructural pseudopolymorph possesses the structural parameters:

$x = 1$ ,  $y = 0$ ,

and is characterized by monoclinic space group  $P2_1$  and unit cell parameters, i.e., crystal axis lengths  $a$ ,  $b$  and  $c$  and angles  $\alpha$ ,  $\beta$  and  $\gamma$  between the crystal axes, at a temperature of 22 °C, of

$a = 16.368(5) \text{ \AA}$ ,

$b = 16.301(3) \text{ \AA}$ ,

$c = 18.408(5) \text{ \AA}$ ,

$\alpha = \gamma = 90^\circ$ , and

$\beta = 110.04(2)^\circ$ .

28. A method for the treatment of bacterial and protozoan infections, and inflammation-related diseases in humans or animals subject thereto, comprising administration to a human or an animal in need of such treatment the pharmaceutical composition containing the substantially pure isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A having Formula I as set forth in claim 25.

29. The method of claim 28, wherein the substantially pure isostructural pseudopolymorph having Formula I is selected from the group of pseudopolymorphs

(Ia)-(Im) set forth below, wherein x, y and S in Formula I, and the average unit cell parameters, i.e., crystal axis lengths a, b and c and angles  $\alpha$ ,  $\beta$  and  $\gamma$  between the crystal axes, of the crystal structures, are:

(Ia) x=1, y=0 and, at 22°C:

$$a = 16.368(5) \text{ \AA},$$

$$b = 16.301(3) \text{ \AA},$$

$$c = 18.408(5) \text{ \AA},$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 110.04(2)^\circ.$$

(Ib) x=1.25, y=1 (S=MeOH) and, at 22°C:

$$a = 16.546(3) \text{ \AA}$$

$$b = 16.185(6) \text{ \AA}$$

$$c = 18.511(7) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 110.53(3)^\circ$$

(Ic) x = 1, y = 0.5 (S = EtOH) and, at - 173°C:

$$a = 16.1400(10) \text{ \AA}$$

$$b = 16.1530(10) \text{ \AA}$$

$$c = 18.2640(10) \text{ \AA}$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 109.590(10)^\circ$$

(Id) x = 1, y = 0.5 (S=n-PrOH) and, at 22°C:

$$a = 16.32(2) \text{ \AA}$$

$$b = 16.344(16) \text{ \AA}$$

$c = 18.610(18) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 108.88(9)^\circ$

(Ie)  $x = 1.5 = y = 0.5$  (S=i-PrOH) and at 22°C:

$a = 16.29410(10) \text{ \AA}$

$b = 16.24440(10) \text{ \AA}$

$c = 18.80600(10) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 108.5701(3)^\circ$

(If)  $x = 1.5 y = 0.5$  (S=n-BuOH) and, at -173°C:

$a = 16.1580(10) \text{ \AA}$

$b = 16.0190(10) \text{ \AA}$

$c = 18.4570(10) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 108.866(10)^\circ$

(Ig)  $x = 1.25 y = 0.5$  (S=i-BuOH) and, at 22°C:

$a = 16.166(8) \text{ \AA}$

$b = 16.123(4) \text{ \AA}$

$c = 18.591(14) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 107.68(14)^\circ$

(Ih)  $x = 1, y = 0.5$  (S=1,2-ethanediol) and, at 22°C:

$a = 16.232(15) \text{ \AA}$

$b = 16.213(10) \text{ \AA}$

$c = 18.531(9) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 109.63(3)^\circ$

(Ii)  $x=1$ ,  $y=0.5$  (S=1,3-propanediol) and, at 22°C:

$a = 16.001(6) \text{ \AA}$

$b = 16.21(2) \text{ \AA}$

$c = 18.497(11) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 109.20(6)^\circ$

(Ij)  $x = 1$ ,  $y=0.5$  (S=glycerol) and, at 22°C:

$a = 16.20(4) \text{ \AA}$

$b = 16.253(13) \text{ \AA}$

$c = 18.613(10) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 109.30(5)^\circ$

(Ik)  $x = 1.5$ ,  $y = 0.5$  (S=glycerol) and, at 22°

$a = 16.303(6) \text{ \AA}$

$b = 16.304(4) \text{ \AA}$

$c = 18.725(13) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$\beta = 108.968(15)^\circ$

(II)  $x = 1.5$ ,  $y=0.5$  (S=acetone) and, at 22°C;

$a = 16.370(6) \text{ \AA}$

$b = 16.235(7) \text{ \AA}$

$c = 18.538(7) \text{ \AA}$

$\alpha = \gamma = 90^\circ$ , and

$$\beta = 109.09(3)^\circ$$

(Im)  $x = 1, y=0.5$  (S=DMSO) and, at 22° C:

$$a = 16.349(3) \text{ \AA}$$

$$b = 16.304(3) \text{ \AA}$$

$$c = 18.401(3)$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 108.948(12)^\circ.$$

30. The method of claim 29 wherein the substantially pure isostructural pseudopolymorph possesses the structural parameters:

$$x = 1, y = 0,$$

and is characterized by monoclinic space group  $P2_1$  and unit cell parameters, i.e., crystal axis lengths  $a$ ,  $b$  and  $c$  and angles  $\alpha$ ,  $\beta$  and  $\gamma$  between the crystal axes, at a temperature of 22 °C, of

$$a = 16.368(5) \text{ \AA},$$

$$b = 16.301(3) \text{ \AA},$$

$$c = 18.408(5) \text{ \AA},$$

$$\alpha = \gamma = 90^\circ, \text{ and}$$

$$\beta = 110.04(2)^\circ.$$




Fig. 1 Crystal packing of 9-deoxo-9-aza-9a-methyl-9a-homocrythromycin A dihydrate (structure coded GEGIAD described in Cambridge Crystallographic Data Base)




Fig. 2 Crystal packing of a new isostuctural pseudopolymer of  $\gamma$ -deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (Ia:  $x = 1, y = 0$ )




Fig. 3 Crystal packing of a new isostructural pseudopolymorph of 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (Ib: S = methanol, x = 1.25; y = 1)




Fig. 4 Crystal packing of a new isostructural pseudopolymorph of  $\gamma$ -dicoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (IC: S = ethanol,  $x = 1$ ;  $y = 0.5$ )




Fig. 5 Crystal packing of a new isostructural pseudopolymer of 9-dcoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (Id:  $S \approx n$ -propanol,  $x = 1$ ;  $y = 0.5$ )




Fig. 6 Crystal packing of a new isostructural pseudopolymer of  $\gamma$ -dicoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (c: S = *iso*-propanol, x = 1.5; y = 0.5)

7/22




Fig. 7 Crystal packing of a new isostructural pseudopolymer of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (if:  $S = n$ -butanol,  $x = 1.5$ ;  $y = 0.5$ )




Fig. 8 Crystal packing of a new isosstructural pseudopolymer of  $\gamma$ -deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (1y: S = *iso*-butanol, x = 1.25; y = 0.5)

9/22




Fig. 9 Crystal packing of a new isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (1h: S = 1,2-ethanediol,  $x = 1$ ;  $y = 0.5$ )




Fig. 10 Crystal packing of a new isostructural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (Li: S = 1.3:propanediol, x = 1; y = 0.5)

11/22




Fig. 11 Crystal packing of a new isostructural pseudopolymorph of 9-deoxo-9a-azza-9a-methyl-9a-homoerythromycin A of the general formula I ([j]: S glycerol, x = 1; y = 0.5)




Fig. 12 Crystal packing of a new isostructural pseudopolymorph of 9-doxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (1k: S = glyccrol,  $x = 1.5$ ;  $y = 0.5$ )




Fig. 13 Crystal packing of a new isosstructural pseudopolymorph of 9-deoxo-9-aza-9a-methyl-9a-homoerythromycin A of the general formula I (II: S = aceton, x = 1; y = 0.5)




Fig. 14 Crystal packing of a new isostuctural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (Im: S = dimethyl sulfoxide,  $x = 1$ ;  $y = 0.5$ )



FIGURE 15: Channel formation within unit cell of isostructural pseudopolymorph of 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A of general Formula I.





FIGURE 16: SEM of the surface of the pseudopolymorph of Formula Ia ( $x=1, y=0$ )




Fig. 17 Dissolution rate of a new isostuctural pseudopolymorph of 9-deoxy-9a-aza-9a-methyl-9a-homoerithromycin A of the general formula I (a: x = 1, y = 0) (Batches 1-3, Example 19) compared with 9-deoxy-9a-aza-9a-methyl-9a-homoerithromycin A dihydrate in the medium pH 3 at 37 °C




Fig. 18 Dissolution rate of a new isostuctural pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerithromycin A of the general formula I (1a:  $x = 1, y = 0$ ) (Batchs 1-3, Example 19) compared with 9-deoxo-9a-aza-9a-methyl-9a-homoerithromycin A dihydrate in the medium pH 6 at 37 °C

19/22



FIGURE 19 Solid state stability of the pseudopolymer (x=1, y=0)

20/22




Fig. 20 - Plasma Profile of Pseudopolymorph Ia and  
9-Deoxo-9a-Aza-9a-Methyl-9a-Homoerythromycin Dihydrate  
in Rats After P.O. Administration (50 mg/kg, b.w.)

21/22




Fig. 21 - Whole Blood Profile of Pseudopolymorph Ia and  
9-Deoxo-9a-Aza-9a-Methyl-9a-Homoerythromycin Dihydrate  
in Rats After P.O. Administration (50 mg/kg, b.w.)

22/22




Fig. 22: Dissolution rate of new isostructural pseudopolymer of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A of the general formula I (Ik: S = glycerol; x = 1.5, y = 0.5) compared with 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A dihydrate in the medium pH 6 at 37°C.